Perfil
Breanna Burkart is the founder of Clovis Oncology, Inc., which was founded in 2009.
She held the title of Head-Investor Relations from 2011 to 2023.
Ms. Burkart's former job was as Director-Investor Relations at Pharmion Corp.
Antiguos cargos conocidos de Breanna Burkart.
Empresas | Cargo | Fin |
---|---|---|
CLOVIS ONCOLOGY, INC. | Founder | 10/07/2023 |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Director/Board Member | 20/07/2009 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Bolsa de valores
- Insiders
- Breanna Burkart